253 related articles for article (PubMed ID: 17353380)
21. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
22. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
[TBL] [Abstract][Full Text] [Related]
23. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
[TBL] [Abstract][Full Text] [Related]
24. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Grosset K; Needleman F; Macphee G; Grosset D
Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
[TBL] [Abstract][Full Text] [Related]
25. Valvular heart disease in patients taking pergolide.
Waller EA; Kaplan J; Heckman MG
Mayo Clin Proc; 2005 Aug; 80(8):1016-20. PubMed ID: 16092580
[TBL] [Abstract][Full Text] [Related]
26. Sudden uncontrollable somnolence and medication use in Parkinson disease.
Avorn J; Schneeweiss S; Sudarsky LR; Benner J; Kiyota Y; Levin R; Glynn RJ
Arch Neurol; 2005 Aug; 62(8):1242-8. PubMed ID: 16087765
[TBL] [Abstract][Full Text] [Related]
27. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
Bares M; Rektorová I; Krajcovicová L; Rektor I
J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
[No Abstract] [Full Text] [Related]
28. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
29. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
[TBL] [Abstract][Full Text] [Related]
30. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
31. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
[No Abstract] [Full Text] [Related]
32. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
[TBL] [Abstract][Full Text] [Related]
33. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
Tran T; Brophy JM; Suissa S; Renoux C
CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
[TBL] [Abstract][Full Text] [Related]
34. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Senol MG; Togrol RE
Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
[No Abstract] [Full Text] [Related]
35. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
36. [Cardiac valvulopathy and dopamine agonist].
Grandas F
Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for the development of pedal edema in patients using pramipexole.
Kleiner-Fisman G; Fisman DN
Arch Neurol; 2007 Jun; 64(6):820-4. PubMed ID: 17420306
[TBL] [Abstract][Full Text] [Related]
38. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Tintner R; Manian P; Gauthier P; Jankovic J
Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
[TBL] [Abstract][Full Text] [Related]
39. [The best of valvular heart disease in 2006].
de Gevigney G;
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():19-28. PubMed ID: 17405561
[TBL] [Abstract][Full Text] [Related]
40. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
Garcia RF; Ordacgi L; Mendlowicz MV; de Freitas GR; Rosso AL; Nazar BP; Fontenelle LF
Cogn Behav Neurol; 2007 Mar; 20(1):11-4. PubMed ID: 17356338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
